Transdermal Estradiol Patches for Hormone Therapy

Pharmacokinetic Advantages

Transdermal 17β-estradiol administration mimics physiological serum estradiol concentrations better than oral formulations by avoiding hepatic first-pass metabolism 1

The transdermal route results in a more beneficial profile on circulating lipids, markers of inflammation, and blood pressure compared to oral administration 1
Transdermal administration minimizes the impact of estrogens on the synthesis of hemostatic factors, reducing thrombotic risk 1, 3
The odds ratio for venous thromboembolism in women using transdermal estrogens was 0.9 (95% CI, 0.4–2.1) compared to 4.2 (95% CI, 1.5–11.6) in women using oral estrogen preparations 3, 4
Transdermal 17βE has been demonstrated to be more effective in achieving bone mineral density peak and reducing bone resorption markers compared to ethinylestradiol-based formulations 1

For patients with chronic skin conditions, oral administration may be necessary as a second choice when transdermal delivery is contraindicated 5

Clinical guidelines strongly recommend transdermal 17βE as the first choice for hormone therapy, particularly in patients with risk factors for thromboembolism 1, 5, 6
For patients requiring hormone replacement therapy without contraception needs, transdermal estradiol is preferred over oral formulations due to its more consistent absorption and favorable safety profile 6
When transdermal administration is contraindicated or refused by the patient, oral 17βE should be considered as a second choice 7